Computational insight of dexamethasone against potential targets of SARS-CoV-2Article Published on 2022-02-012023-07-06 Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), [키워드] COVID-19 Dexamethasone glucocorticoid Interleukins main protease SARS-CoV-2 [DOI] 10.1080/07391102.2020.1819880 PMC 바로가기
Consequences of the first and second COVID-19 wave on kidney transplant recipients at a large Indian transplant centre인도의 대형 이식 센터에서 신장 이식 환자에 대한 첫 번째 및 두 번째 COVID-19 물결의 결과Article Published on 2022-02-012022-09-11 Journal: Nephrology (Carlton, Vic.) [Category] COVID19(2023년), SARS, 치료제, [키워드] 28-day mortality co-morbidity conducted consequence cough COVID-19 COVID-19 positive patient Dexamethasone Fever First wave Hydroxychloroquine ICU admission ICU admissions India kidney transplant kidney transplant recipient kidney transplant recipients less lymphocyte Lymphocyte count lymphocyte counts morbidities Mortality mortality rate Mucormycosis neutrophil Neutrophils not different P-value paediatric patient paediatric patients percentage percentages positive patients reduced Remdesivir Retrospective study scarcity second wave Serum ferritin Tocilizumab utilization with COVID-19 [DOI] 10.1111/nep.13961 PMC 바로가기 [Article Type] Article
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasoneArticle Published on 2022-02-012023-07-06 Journal: Journal of Thrombosis and Thrombolysis [Category] COVID19(2023년), [키워드] Anticoagulants apixaban COVID-19 Dexamethasone Embolism rivaroxaban thrombosis [DOI] 10.1007/s11239-021-02561-w PMC 바로가기
Oral dexamethasone for COVID-19 patients at the initial recognition of hypoxia: Can an early dose herald a better outcome?Article Published on 2022-02-012023-07-06 Journal: Journal of microbiology, immunology, and infection [Category] COVID19(2023년), [키워드] COVID-19 Dexamethasone hypoxia steroid [DOI] 10.1016/j.jmii.2021.07.016 PMC 바로가기
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumoniaArticle Published on 2022-02-012023-07-07 Journal: Pulmonary pharmacology & therapeutics [Category] COVID19(2023년), [키워드] COVID-19 Dexamethasone dose Pneumonia Predicted body weight. [DOI] 10.1016/j.pupt.2021.102108 PMC 바로가기
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID studyObservational Study Published on 2022-02-012022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Active surveillance acute respiratory distress adjusted age analysed Analysis anti-IL-6 association case report forms collected criteria death Dexamethasone discharge eligible participant enrolled Follow-up French fungal Fungal infection fungal pathogen groups hazard ratio high mortality high risk highlight ICU ICU admission ICUs identify IFI Infection intensive care intensive care unit invasive knowledge mechanical ventilation mechanically ventilated patient mechanically ventilated patients men microorganism Mortality Mucormycosis multicentre Multivariate analysis National Observational cohort study Odds ratio Older outcome Patient performed Pfizer Population Prevalence Primary outcome Registered regression models risk factor Risk factors SARS-COV-2 infection screened secondary severe COVID-19 significantly higher solid organ transplantation survival curve syndrome Treatment variable with COVID-19 [DOI] 10.1016/S2213-2600(21)00442-2 PMC 바로가기 [Article Type] Observational Study
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trialsCOVID-19, SARS, MER 또는 인플루엔자로 입원 한 환자의 글루코 코르티코이드, 심혈관 합병증 및 사망률의 전신 투여 : 무작위 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-02-012022-09-10 Journal: Pharmacological research [Category] COVID19(2023년), MERS, SARS, 임상, [키워드] 95% CI administration all-cause mortality benefit cardiometabolic cardiovascular complication cardiovascular complications Confidence intervals COVID-19 Dexamethasone Effects estimate Follow-up glucocorticoid Glucocorticoids hospitalised in-hospital mortality Influenza lower mortality Mantel-Haenszel mechanical ventilation MERS Meta-analysis Mortality objective outcomes oxygen Patient patients Placebo random effect randomisation Randomised trial randomised trials receiving reduce reduce mortality reduced reduction renal function reported respiratory Respiratory Support respiratory viral infections Result risk severe COVID-19 significantly standard care Steroids subgroup subgroups systematic review systemic systemic glucocorticoid systemic glucocorticoids Treatment trials Viral was reduced were used with COVID-19 worsening [DOI] 10.1016/j.phrs.2021.106053 PMC 바로가기 [Article Type] Meta-Analysis
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trialRandomized Controlled Trial Published on 2022-02-012022-10-05 Journal: Pharmacological Reports [Category] 임상, [키워드] 95% CI adverse effect adverse event Analysis assigned clinical clinical response competing COVID-19 death Dexamethasone Diagnosis different dose dose Efficacy Efficacy and safety groups High-dose high-dose group hospital discharge hospitalized patient hyperglycemia IMPROVE incidence increase in Intermediate-dose intravenous low-dose moderate not significantly different outcome Patient randomized clinical trial risk severe COVID-19 Side effect significantly survival Treatment with COVID-19 [DOI] 10.1007/s43440-021-00341-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic StudyICU에 입원한 COVID-19 환자에서 토실리주맙의 고정 용량을 향하여: 관찰 인구 약동학 및 기술 약력학 연구의 결과Observational Study Published on 2022-02-012022-09-12 Journal: Clinical pharmacokinetics [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] added Admission age Analysis applied AUC average clearance Concentration concomitant therapy coronavirus disease covariate COVID-19 COVID-19 patients COVID-19 treatment guidelines Dexamethasone dexamethasone 6 mg distribution dose dose administration Dosing dosing schedules eligible elimination rate enrolled Evidence Final first dose fixed fixed dose ICU identify IMPROVE increase indications intensive care intravenous tocilizumab investigated linear mechanical ventilation mixed-effects model nasal obesity Older Open-label outcome oxygen support parameter pathway Patient patients performed Pharmacodynamic pharmacokinetic plasma sample polymerase chain Population provide raised Randomized controlled trial receptor REMAP-CAP Result risk factor Safe saturated severe COVID-19 shown Support survival Tocilizumab Variability Volume was performed [DOI] 10.1007/s40262-021-01074-2 PMC 바로가기 [Article Type] Observational Study
Development and Validation of a Novel HPLC Method to Analyse Metabolic Reaction Products Catalysed by the CYP3A2 Isoform: In Vitro Inhibition of CYP3A2 Enzyme Activity by Aspirin (Drugs Often Used Together in COVID-19 Treatment)Article Published on 2022-01-292022-10-30 Journal: Molecules [Category] Coronavirus, SARS, [키워드] 6β-hydroxydexamethasone Accuracy activity applied Aspirin bridge Chromatography competitive inhibitor Concentration COVID-19 CYP3A activity CYP3A2 cytochrome P450 development Dexamethasone drug drug interaction enzyme activity evaluate Fever harmonization healthcare HPLC ICH in vitro indicated Inflammation inhibit inhibition inhibitor International Conference limit limit of detection liquid liver metabolic moderate novel Pain Precision product quantification reaction reversed risk Severe case stability Toxicity treat validation [DOI] 10.3390/molecules27030927 PMC 바로가기 [Article Type] Article